Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib

BACKGROUND: The mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma (RCC). Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in enhanced anticancer activity. METHODS: All...

Descripción completa

Detalles Bibliográficos
Autores principales: Flaig, T W, Costa, L J, Gustafson, D L, Breaker, K, Schultz, M K, Crighton, F, Kim, F J, Drabkin, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966634/
https://www.ncbi.nlm.nih.gov/pubmed/20823888
http://dx.doi.org/10.1038/sj.bjc.6605868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966634/
https://www.ncbi.nlm.nih.gov/pubmed/20823888
http://dx.doi.org/10.1038/sj.bjc.6605868

Ejemplares similares